tofacitinib
Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study
November 12, 2019Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib
Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis
Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
Pfizer’s Xeljanz denied plaque psoriasis indication by FDA
October 16, 2015Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib
The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Mixed tale for Pfizer psoriasis drug
October 11, 2013Sales and Marketing Enbrel, Pfizer, psoriasis, tofacitinib
Pfizer has seen its novel, oral Janus kinase (JAK) inhibitor tofacitinib turn in a mixed showing in late-stage trials in …
New data for Pfizer arthritis pill
September 18, 2012Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib
Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …
Pfizer’s arthritis drug delayed by FDA
August 21, 2012Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
Pfizer says its new rheumatoid arthritis drug tofacitinib has been delayed by the FDA. Tofacitinib, an oral Janus kinase (JAK) …
Pfizer’s RA drug on course for approval
May 10, 2012Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib
An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …
FDA accepts Pfizer’s arthritis pill for review
December 22, 2011Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …
EMA accepts submission of Pfizer’s new arthritis drug
November 21, 2011Research and Development, Sales and Marketing EMA, Pfizer, tofacitinib
The European Medicines Agency has accepted Pfizer’s arthritis drug tofacitinib for review.Tofacitinib is a novel, oral JAK inhibitor being studied …
Deaths reported in Pfizer arthritis trial
April 26, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …
Phase III boost for Pfizer’s oral arthritis drug
April 18, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
